LRRN4CL Activators
LRRN4CL can initiate various cellular signaling pathways that lead to its activation. Forskolin, by directly stimulating adenylyl cyclase, elevates intracellular cAMP levels, thus activating protein kinase A (PKA). PKA, in turn, can phosphorylate numerous cellular substrates, including those involved in the activation of LRRN4CL. Similarly, Isoproterenol, functioning as a beta-adrenergic agonist, also raises cAMP levels through the activation of beta-adrenergic receptors, which likely triggers PKA to phosphorylate components of the LRRN4CL signaling pathway. IBMX, as a non-selective inhibitor of phosphodiesterases that degrade cAMP and cGMP, increases the levels of these cyclic nucleotides, potentially resulting in PKA or PKG activation and subsequent phosphorylation of proteins associated with LRRN4CL. Epinephrine, engaging with adrenergic receptors, leads to the activation of adenylyl cyclase and an increase in cAMP, with the ensuing PKA activation possibly leading to phosphorylation of proteins that play a role in LRRN4CL's activation.
Rolipram, by selectively inhibiting PDE4, prevents the breakdown of cAMP and hence enhances PKA activity, which can lead to the phosphorylation and activation of LRRN4CL-associated proteins. Anisomycin, though primarily known as a protein synthesis inhibitor, can activate stress-activated protein kinases like JNK, which might phosphorylate proteins that interact with LRRN4CL. PMA serves as an activator of protein kinase C (PKC), which is implicated in several signaling cascades and can phosphorylate proteins involved in LRRN4CL activation. Inhibitors such as PF-4708671, LY294002, SB203580, Y-27632, and Sp600125 disrupt the activity of specific kinases or signaling molecules, leading to compensatory activation of alternative pathways. These pathways often involve kinase cascades that can culminate in the phosphorylation and activation of proteins associated with the LRRN4CL signaling network.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin activates adenylyl cyclase, leading to an increase in cyclic AMP (cAMP) levels. Elevated cAMP may enhance LRRN4CL activation through PKA-dependent phosphorylation, as cAMP is a secondary messenger known to regulate a wide array of cellular functions, including those related to neuronal signaling and protein phosphorylation. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $27.00 $37.00 | 5 | |
Isoproterenol is a beta-adrenergic agonist that stimulates adenylyl cyclase activity via beta-adrenergic receptors, increasing cAMP levels in cells. This rise in cAMP is likely to activate protein kinase A (PKA), which can then phosphorylate substrates involved in the signaling pathways associated with LRRN4CL activation. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases (PDEs), which degrade cAMP and cGMP. By inhibiting PDEs, IBMX increases cAMP and cGMP levels within the cell, which could result in the activation of PKA or PKG, kinases that could phosphorylate and activate proteins in the LRRN4CL pathway. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $40.00 $102.00 $197.00 $1739.00 $16325.00 | ||
Epinephrine interacts with adrenergic receptors, leading to the activation of adenylyl cyclase and an increase in cAMP levels. The subsequent activation of PKA could result in the phosphorylation of proteins involved in the signaling pathways that include LRRN4CL, leading to its activation. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Rolipram is a selective inhibitor of phosphodiesterase 4 (PDE4), which specifically degrades cAMP. Inhibition of PDE4 by Rolipram results in increased cAMP levels and subsequent activation of PKA, which may phosphorylate proteins within the LRRN4CL-associated signaling pathways. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $97.00 $254.00 | 36 | |
Anisomycin is a protein synthesis inhibitor that can activate stress-activated protein kinases (SAPKs), such as JNK. Activation of these kinases can lead to downstream phosphorylation events that may include proteins interacting directly or indirectly with LRRN4CL, resulting in its functional activation. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA is a potent activator of protein kinase C (PKC), which is involved in numerous signaling cascades. PKC activation could lead to the phosphorylation of proteins that are part of the signaling pathways involving LRRN4CL, thereby activating LRRN4CL. | ||||||
PF 4708671 | 1255517-76-0 | sc-361288 sc-361288A | 10 mg 50 mg | $175.00 $700.00 | 9 | |
PF-4708671 is a selective inhibitor of p70S6 kinase (S6K1), and its inhibition can lead to compensatory activation of other kinases in the mTOR signaling pathway. These kinases could phosphorylate substrates relevant to LRRN4CL activation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3 kinase inhibitor, and its inhibition leads to altered signaling downstream of PI3K. This alteration can activate compensatory pathways that may involve kinase cascades capable of phosphorylating and activating LRRN4CL. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is an inhibitor of p38 MAP kinase, which may lead to the activation of alternative signaling pathways as a compensatory mechanism. These alternative pathways could involve kinases that phosphorylate and activate LRRN4CL. | ||||||